Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells

Abstract

Expression of endothelin (ET)-1 is increased in endothelial cells exposed to angiotensin II (Ang II), leading to endothelial dysfunction and cardiovascular disorders. Since von Willebrand Factor (vWF) blockade improves endothelial function in coronary patients, we hypothesized that targeting endothelial vWF with short interference RNA (siRNA) prevents Ang II-induced ET-1 upregulation. Nearly 65 ± 2% silencing of vWF in porcine aortic endothelial cells (PAOECs) was achieved with vWF-specific siRNA without affecting cell viability and growth. While showing ET-1 similar to wild type cells at rest, vWF-silenced cells did not present ET-1 upregulation during exposure to Ang II (100 nM/24 h), preserving levels of endothelial nitric oxide synthase activity similar to wild type. vWF silencing prevented AngII-induced increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) activity and superoxide anion (O2−) levels, known triggers of ET-1 expression. Moreover, no increase in O2− or ET-1 levels was found in silenced cells treated with AngII or NOX-agonist phorbol ester (PMA 5 nM/48 h). Finally, vWF was required for overexpression of NOX4 and NOX2 in response to AngII and PMA. In conclusion, endothelial vWF knockdown prevented Ang II-induced ET-1 upregulation through attenuation of NOX-mediated O2− production. Our findings reveal a new role of vWF in preventing of Ang II-induced endothelial dysfunction.

Endothelial function is disturbed in a hypertensive diabetic animal model of HFpEF: Moderate continuous vs. high intensity interval training

“…This activation pathway was recently documented in porcine aortic cells, where the angiotensin-II mediated elevation of NADPH-oxidase expression was associated with the activation of JNK. 38 Our observation of reduced eNOS expression/activation in the present HFpEF model is in line with earlier studies in other animal models such as hypertensive rats 23 and senescence-accelerated mice. 24 What is the molecular trigger leading to a reduced expression of eNOS and an elevation of NADPH oxidase expression?…”

COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches

“…Contrary to ACE, which converts angiotensin I (Ang I) to angiotensin II (Ang II), ACE2 is mainly involved in the degradation of Ang II, thereby resulting in the formation of Ang 1-7 (Turner et al 2004;Tikellis et al 2011). While Ang II induces vasoconstrictive, proinflammatory and pro-oxidative effects by increasing the expression on endothelial von Willebrand factor and by activating the endothelial Ang II receptor type 1 (AT1) (Dushpanova et al 2016), Ang 1-7 mediates anti-inflammatory, anti-oxidative and vasodilatory effects through binding Mas receptor (MasR), thus exerting a beneficial effect in several pathological conditions, such as hypertension, diabetes, and CVD (Tikellis et al 2011 and reference therein). In order to maintain homeostasis, ACE2 opposes the actions of Ang II and negatively regulates RAS.…”

Oleanolic acid alleviates diabetic rat carotid artery injury through the inhibition of NLRP3 inflammasome signaling pathways

“…STZ, streptozotocin. vasoconstrictor, and its increase in endothelial cells leads to endothelial dysfunction and cardiovascular disorders (20). NO is the most important vascular relaxing factor, which is also regulated in the endothelium, and alterations in the endothelial production of NO are known to correlate with endothelial dysfunction (21).…”